M&A Deal Summary |
|
|---|---|
| Date | 2020-12-15 |
| Target | Mallax Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Impilo |
| Deal Type | Buyout (LBO, MBO, MBI) |
SEARCH BY
Impilo is a private investment firm focused exclusively on on investments in Nordic companies operating in the pharmaceutical, medical technology, healthcare services and other health-related industries. Impilo prefers majority investments, but will consider select minority situations. Target companies are generally valued between SEK 200 million and SEK 1.5 billion. Impilo has offices in Stockholm and Copenhagen.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 10 |
| Sector: Life Science M&A | 2 of 3 |
| Type: Buyout (LBO, MBO, MBI) M&A Deals | 5 of 8 |
| Country: Sweden M&A | 4 of 4 |
| Year: 2020 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-09-03 |
Euro Accident
Danderyd, Sweden Euro Accident provides health-related insurance and employee wellbeing, active primarily within the long-term disability (LTD), private health insurance (PHI), group life, and accident markets. Euro Accident was founded in 1996 and is based in Danderyd, Sweden. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-01-20 |
Scantox
Lille Skensved, Denmark Scantox is a GLP (“Good Laboratory Practice”) accredited CRO, providing pre-clinical research services, including regulatory in-vivo toxicology studies, that are critical to any drug development process. Scantox was founded in 1977 and is based in Lille Skensved, Denmark. |
Buy | - |
